Jason P. Rhodes - 01 Apr 2022 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Reporting relationship: Director
Issuer ticker: REPL
Reported as of: 01 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Apr 2022, 16:13:35 UTC
Prior SEC filing: 06 Oct 2021
Next SEC filing: 06 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jean Franchi, attorney-in-fact

Key filing fact

Jason P. Rhodes filed Form 4 for Replimune Group, Inc. (REPL) on 05 Apr 2022.

Key facts

This page summarizes Jason P. Rhodes's Form 4 filing for Replimune Group, Inc. (REPL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Apr 2022, 16:13.

Change

Previous filing in this sequence was filed on 06 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REPL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +16,500
Change %
Price: $0.000000
Shares after: 16,500
Date: 01 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,500
Exercise price: $18.26
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted on April 1, 2022 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2023.

Footnote F2

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.